Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
EBAG9 tempers lymphocyte killing activity
Gaël Ménasché, Geneviève de Saint Basile
Gaël Ménasché, Geneviève de Saint Basile
Published July 20, 2009
Citation Information: J Clin Invest. 2009;119(8):2136-2140. https://doi.org/10.1172/JCI40270.
View: Text | PDF
Commentary

EBAG9 tempers lymphocyte killing activity

  • Text
  • PDF
Abstract

The cytotoxic activity of lymphocytes is crucial for immune surveillance and homeostasis. Several independent, naturally occurring genetic models characterized by defects in granule trafficking or exocytosis have helped to decipher the multiple steps and molecules that regulate the cytotoxic process. The study by Rüder and colleagues in this issue of the JCI shows that an engineered absence of EBAG9, previously reported as a tumor-associated antigen, enhances cytotoxic activity of CTLs but not NK cells, likely acting on the endosomal-lysosomal trafficking of the cytotoxic effectors (see the related article beginning on page 2184). This finding adds a new piece to the puzzle of complex mechanisms that tightly regulate the capacity of the cytotoxic response and suggests a new target to negatively modulate CTL responsiveness.

Authors

Gaël Ménasché, Geneviève de Saint Basile

×

Figure 1

Sorting proteins to the cytotoxic granules/secretory lysosomes.

Options: View larger image (or click on image) Download as PowerPoint
Sorting proteins to the cytotoxic granules/secretory lysosomes.
The newl...
The newly synthesized soluble proteins granzymes A and B acquire the mannose-6-phosphate signal in the Golgi complex, enabling their association with the mannose-6-phosphate receptor (M6PR) in the trans-Golgi network (TGN) and transport to early endosomes before they are sorted to late endosomes. LAMP1 is sorted by AP complexes (not shown) and transported from the plasma membrane to the endosomes, preferentially to the perimeter membrane of the multivesicular bodies (MVBs) in the sorting endosome and then to the late endosome and cytotoxic granule/LRO. Early endosomes sort cargoes to different destinations. Cargoes can be recycled back to the plasma membrane via fast or slow pathways, delivered to the lysosomes through sorting endosomes and multivesicular bodies, or sorted to the trans-Golgi network. BLOC-1 is involved in the exit of cargoes from an early endosome subdomain toward intermediate/sorting endosomes. γ2-Adaptin has been reported (19) to associate with the ubiquitin machinery, which directs cargo incorporation into intraluminal vesicles (ILVs) of multivesicular bodies by the ESCRT machinery. The study by Rüder et al. in this issue of the JCI (11) reports that EBAG9 associates with and inhibits γ2-adaptin and associates with two BLOC-1 subunits. Loss of EBAG9 enhances the cytotoxic activity of T lymphocytes, likely acting on the endosomal-lysosomal trafficking of the cytotoxic effectors. Although the detailed mechanism accounting for the transport of perforin from the trans-Golgi network to late endosomes is still poorly understood, the findings of Rüder et al. (11) suggest a connection among granzymes and perforin trafficking, the BLOC-1 components, and the ESCRT machinery.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts